Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

FDA Approves Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) for a First-Line Combination Regimen when Combined w ith LAZCLUZE (lazertinib)

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers, and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education

It is important that our members are aware of meetings, webinars, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation

The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board

MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
Report Broken Link

Welcome

Complete Story

01/21/2026

Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

FDA Approves Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) for a First-Line Combination Regimen when Combined with LAZCLUZE (lazertinib)

Advocacy

Education

Research

MSHO Foundation

Job Board

Report Broken Links

FDA Approves Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) for a First-Line Combination Regimen when Combined w ith LAZCLUZE (lazertinib)